• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人工甜味剂与非酒精性脂肪性肝病相关:微生物群失调作为一种新的潜在机制。

Artificial sweeteners are related to non-alcoholic fatty liver disease: Microbiota dysbiosis as a novel potential mechanism.

作者信息

Emamat Hadi, Ghalandari Hamid, Tangestani Hadith, Abdollahi Afsoun, Hekmatdoost Azita

机构信息

Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

出版信息

EXCLI J. 2020 May 12;19:620-626. doi: 10.17179/excli2020-1226. eCollection 2020.

DOI:10.17179/excli2020-1226
PMID:32483408
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7257251/
Abstract

Non-alcoholic fatty liver disease (NAFLD) is a systemic and wide-spread disease characterized by accumulation of excess fat in the liver of people who drink little or no alcohol. Artificial sweeteners (ASs) or sugar substitutes are food additives that provide a sweet taste, and are also known as low-calorie or non-calorie sweeteners. Recently people consume increasingly more ASs to reduce their calorie intake. Gut microbiome is a complex ecosystem where 10 microorganisms play several roles in host nutrition, bone mineralization, immune system regulation, xenobiotics metabolism, proliferation of intestinal cells, and protection against pathogens. A disruption in composition of the normal microbiota is known as 'gut dysbiosis' which may adversely affect body metabolism. It has recently been suggested that dysbiosis may contribute to the occurrence of NAFLD. The aim of the present study was to investigate the effects of ASs on the risk of NAFLD. The focus of this review is on microbiota changes and dysbiosis. Increasing evidence shows that ASs have a potential role in microbiota alteration and dysbiosis. We speculate that increased consumption of ASs can further raise the prevalence of NAFLD. However, further human studies are needed to determine this relationship definitively.

摘要

非酒精性脂肪性肝病(NAFLD)是一种全身性广泛疾病,其特征是在很少饮酒或不饮酒的人群肝脏中积累过多脂肪。人工甜味剂(ASs)或代糖是提供甜味的食品添加剂,也被称为低热量或无热量甜味剂。近来,人们越来越多地食用人工甜味剂以减少热量摄入。肠道微生物群是一个复杂的生态系统,其中的微生物在宿主营养、骨矿化、免疫系统调节、外源性物质代谢、肠道细胞增殖以及抵御病原体等方面发挥多种作用。正常微生物群组成的破坏被称为“肠道菌群失调”,这可能会对身体代谢产生不利影响。最近有人提出,菌群失调可能导致NAFLD的发生。本研究的目的是调查人工甜味剂对NAFLD风险的影响。本综述的重点是微生物群的变化和菌群失调。越来越多的证据表明,人工甜味剂在微生物群改变和菌群失调中具有潜在作用。我们推测,人工甜味剂消费的增加会进一步提高NAFLD的患病率。然而,需要进一步的人体研究来明确确定这种关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/670a/7257251/345edb108808/EXCLI-19-620-t-001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/670a/7257251/345edb108808/EXCLI-19-620-t-001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/670a/7257251/345edb108808/EXCLI-19-620-t-001.jpg

相似文献

1
Artificial sweeteners are related to non-alcoholic fatty liver disease: Microbiota dysbiosis as a novel potential mechanism.人工甜味剂与非酒精性脂肪性肝病相关:微生物群失调作为一种新的潜在机制。
EXCLI J. 2020 May 12;19:620-626. doi: 10.17179/excli2020-1226. eCollection 2020.
2
Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease.系统评价:微生物失调与非酒精性脂肪性肝病。
Aliment Pharmacol Ther. 2015 Nov;42(9):1051-63. doi: 10.1111/apt.13376. Epub 2015 Aug 24.
3
Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.槲皮素对高脂饮食诱导的小鼠非酒精性脂肪性肝病的保护作用是通过调节肠道微生物群失衡和相关肠-肝轴激活来介导的。
Free Radic Biol Med. 2017 Jan;102:188-202. doi: 10.1016/j.freeradbiomed.2016.11.037. Epub 2016 Nov 25.
4
New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer.肠道微生物群在非酒精性脂肪性肝病及其相关肝癌中的新见解和治疗意义。
Cancer Lett. 2019 Sep 10;459:186-191. doi: 10.1016/j.canlet.2019.114425. Epub 2019 Jun 8.
5
Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents.肠道微生物群在儿童和青少年非酒精性脂肪性肝病调控中的作用
Front Nutr. 2021 Jun 25;8:700058. doi: 10.3389/fnut.2021.700058. eCollection 2021.
6
Obesity, fatty liver disease and intestinal microbiota.肥胖、脂肪肝疾病与肠道微生物群
World J Gastroenterol. 2014 Nov 28;20(44):16452-63. doi: 10.3748/wjg.v20.i44.16452.
7
Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?益生菌在非酒精性脂肪性肝病中的作用:肠道微生物组是否重要?
Nutrients. 2019 Nov 19;11(11):2837. doi: 10.3390/nu11112837.
8
Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease.非酒精性脂肪性肝病患者的肠道菌群失调。
Hepatobiliary Pancreat Dis Int. 2017 Aug 15;16(4):375-381. doi: 10.1016/S1499-3872(17)60019-5.
9
Gut microbiota and non-alcoholic fatty liver disease.肠道微生物群与非酒精性脂肪性肝病
Hepatobiliary Pancreat Dis Int. 2015 Dec;14(6):572-81. doi: 10.1016/s1499-3872(15)60026-1.
10
Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.肠道微生物群:非酒精性脂肪性肝病的新治疗靶点。
Expert Rev Gastroenterol Hepatol. 2019 Mar;13(3):193-204. doi: 10.1080/17474124.2019.1569513. Epub 2019 Jan 25.

引用本文的文献

1
Rediscovering Sweetness: The Evolution and Impact of Non-Nutritive and Natural Sweeteners.重新发现甜味:非营养性甜味剂和天然甜味剂的演变与影响
Curr Nutr Rep. 2025 Apr 2;14(1):54. doi: 10.1007/s13668-025-00646-z.
2
Chronic Use of Artificial Sweeteners: Pros and Cons.长期食用人工甜味剂:利弊分析。
Nutrients. 2024 Sep 19;16(18):3162. doi: 10.3390/nu16183162.
3
Consuming artificial sweeteners may alter the structure and function of duodenal microbial communities.食用人工甜味剂可能会改变十二指肠微生物群落的结构和功能。

本文引用的文献

1
Revisited: Assessing the in vivo data on low/no-calorie sweeteners and the gut microbiota.重新审视:评估低/无热量甜味剂与肠道微生物组的体内数据。
Food Chem Toxicol. 2019 Oct;132:110692. doi: 10.1016/j.fct.2019.110692. Epub 2019 Jul 24.
2
Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH).肠道菌群与非酒精性脂肪性肝病/非酒精性脂肪性肝炎(NAFLD/NASH)。
Ann Hepatol. 2019 May-Jun;18(3):416-421. doi: 10.1016/j.aohep.2019.04.006. Epub 2019 Apr 16.
3
Effects of Sweeteners on the Gut Microbiota: A Review of Experimental Studies and Clinical Trials.
iScience. 2023 Nov 23;26(12):108530. doi: 10.1016/j.isci.2023.108530. eCollection 2023 Dec 15.
4
Sugar-Sweetened Beverages and Artificially Sweetened Beverages Consumption and the Risk of Nonalcoholic Fatty Liver (NAFLD) and Nonalcoholic Steatohepatitis (NASH).糖饮料和人工甜味饮料的消费与非酒精性脂肪肝(NAFLD)和非酒精性脂肪性肝炎(NASH)的风险。
Nutrients. 2023 Sep 15;15(18):3997. doi: 10.3390/nu15183997.
5
Sugar-Sweetened and Artificially Sweetened Beverages and Risk of Liver Cancer and Chronic Liver Disease Mortality.糖和人工甜味饮料与肝癌和慢性肝病死亡率的关系。
JAMA. 2023 Aug 8;330(6):537-546. doi: 10.1001/jama.2023.12618.
6
Ultra-Processed Food Intake Is Associated with Non-Alcoholic Fatty Liver Disease in Adults: A Systematic Review and Meta-Analysis.超高加工食品摄入与成年人非酒精性脂肪肝疾病的相关性:系统评价和荟萃分析。
Nutrients. 2023 May 10;15(10):2266. doi: 10.3390/nu15102266.
7
Association Between NLR and NAFLD in Adults Exposed to Famine in Early Life.早年经历饥荒的成年人中中性粒细胞与淋巴细胞比值(NLR)和非酒精性脂肪性肝病(NAFLD)之间的关联
Risk Manag Healthc Policy. 2022 Aug 23;15:1561-1568. doi: 10.2147/RMHP.S368369. eCollection 2022.
8
Lifestyle as well as metabolic syndrome and non-alcoholic fatty liver disease: an umbrella review of evidence from observational studies and randomized controlled trials.生活方式以及代谢综合征和非酒精性脂肪肝:来自观察性研究和随机对照试验的证据的伞式综述。
BMC Endocr Disord. 2022 Apr 10;22(1):95. doi: 10.1186/s12902-022-01015-5.
9
Sugar-Sweetened Beverage, Diet Soda, and Nonalcoholic Fatty Liver Disease Over 6 Years: The Framingham Heart Study.6年期间的含糖饮料、无糖汽水与非酒精性脂肪性肝病:弗雷明汉心脏研究
Clin Gastroenterol Hepatol. 2022 Nov;20(11):2524-2532.e2. doi: 10.1016/j.cgh.2021.11.001. Epub 2021 Nov 6.
10
Nutritional Implications of Patients with Dysautonomia and Hypermobility Syndromes.自主神经功能障碍和高活动性综合征患者的营养问题。
Curr Nutr Rep. 2021 Dec;10(4):324-333. doi: 10.1007/s13668-021-00373-1. Epub 2021 Sep 12.
甜味剂对肠道微生物群的影响:实验研究和临床试验综述。
Adv Nutr. 2019 Jan 1;10(suppl_1):S31-S48. doi: 10.1093/advances/nmy037.
4
Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease.肠道微生物衍生介质作为非酒精性脂肪性肝病的潜在标志物。
Biomed Res Int. 2019 Jan 2;2019:8507583. doi: 10.1155/2019/8507583. eCollection 2019.
5
The role of the microbiome in NAFLD and NASH.微生物组在非酒精性脂肪性肝病和非酒精性脂肪性肝炎中的作用。
EMBO Mol Med. 2019 Feb;11(2). doi: 10.15252/emmm.201809302.
6
Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics.肥胖与非酒精性脂肪性肝病:从病理生理学到治疗学。
Metabolism. 2019 Mar;92:82-97. doi: 10.1016/j.metabol.2018.11.014. Epub 2018 Nov 29.
7
Intestinal Immune Dysregulation Driven by Dysbiosis Promotes Barrier Disruption and Bacterial Translocation in Rats With Cirrhosis.肠道菌群失调驱动的免疫失调促进肝硬化大鼠的屏障破坏和细菌易位。
Hepatology. 2019 Sep;70(3):925-938. doi: 10.1002/hep.30349. Epub 2019 Mar 5.
8
Role of Gut Microbiota-Generated Short-Chain Fatty Acids in Metabolic and Cardiovascular Health.肠道微生物群衍生的短链脂肪酸在代谢和心血管健康中的作用。
Curr Nutr Rep. 2018 Dec;7(4):198-206. doi: 10.1007/s13668-018-0248-8.
9
Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women.非糖尿病肥胖女性肝脂肪变性的分子表型和宏基因组学。
Nat Med. 2018 Jul;24(7):1070-1080. doi: 10.1038/s41591-018-0061-3. Epub 2018 Jun 25.
10
Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease.肠道微生物群的变化、生态失调、炎症与非酒精性脂肪性肝病
Front Microbiol. 2018 Jan 30;9:61. doi: 10.3389/fmicb.2018.00061. eCollection 2018.